Anti-metabolites
Combination Chemotherapy for Colorectal Cancer
Recruiting1 awardPhase 2
Tampa, Florida
This trial tests a combination of three drugs to treat advanced colorectal cancer. It targets patients whose cancer has spread or cannot be surgically removed. The drugs work together to kill cancer cells, block their growth, and help the immune system fight the cancer. Oxaliplatin is a new drug that has been recently added to initial treatments for advanced colorectal cancer.
Monoclonal Antibodies
Encorafenib + Cetuximab + Nivolumab for Colorectal Cancer
Recruiting1 awardPhase 1 & 2
Houston, Texas
This trial is testing a combination of drugs to treat patients with colorectal cancer that has spread and cannot be removed by surgery. The drugs work by blocking enzymes needed for cell growth and by helping the body's immune system attack the cancer.
Popular Filters
Trials for Colorectal Cancer Patients
Educational Videos for Colorectal Cancer
Recruiting1 award1 criteria
Chapel Hill, North Carolina
This trial aims to study how to improve the participation of Latinos in cancer clinical trials. They will recruit 60 Spanish-speaking individuals from a church in Chapel Hill. Participants will attend an educational session and watch
Monoclonal Antibodies
Dostarlimab for Rectal Cancer
Recruiting1 awardPhase 2
Little Rock, Arkansas
This trial is testing a drug called dostarlimab on patients with a specific type of rectal cancer who haven't been treated before. The goal is to see if this drug alone can treat the cancer effectively, so patients might avoid more aggressive treatments like chemotherapy, radiation, and surgery. Dostarlimab (Jemperliâ„¢) has been approved in the EU and USA for treating certain types of cancer.
Antimetabolite
Galunisertib + Chemotherapy for Rectal Cancer
Recruiting1 awardPhase 2
Portland, Oregon
This trial is testing a new drug to treat rectal cancer in combination with chemotherapy and radiation. Tissue and blood samples will also be collected to study the effectiveness of the drug and the immune system's response.
Trials for Colon Cancer Patients
Educational Videos for Colorectal Cancer
Recruiting1 award1 criteria
Chapel Hill, North Carolina
This trial aims to study how to improve the participation of Latinos in cancer clinical trials. They will recruit 60 Spanish-speaking individuals from a church in Chapel Hill. Participants will attend an educational session and watch
Platinum-based Chemotherapy
Radiation Therapy + Fluorouracil for Rectal Cancer
Recruiting1 awardPhase 2
Concord, California
This trial tests if combining radiation therapy with chemotherapy can shrink tumors in patients with stage II or III rectal cancer. The treatment aims to make tumors smaller and easier to remove while protecting normal cells. The study will also look at the timing of treatments and their effects on surgery and recovery.
Trials for Metastatic Patients
Antimetabolite
Galunisertib + Chemotherapy for Rectal Cancer
Recruiting1 awardPhase 2
Portland, Oregon
This trial is testing a new drug to treat rectal cancer in combination with chemotherapy and radiation. Tissue and blood samples will also be collected to study the effectiveness of the drug and the immune system's response.
CDK4/6 Inhibitor
LY3214996 + Cetuximab / Abemaciclib for Colorectal Cancer
Recruiting1 awardPhase 1 & 2
Houston, Texas
This trial is investigating the side effects and best dosage of LY3214996 when given with cetuximab to treat patients with unresectable and/or metastatic colorectal cancer. Cetuximab is an antibody that may interfere with the ability of tumor cells to grow and spread, while LY3214996 and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Checkpoint Inhibitor
Regorafenib + Immunotherapy for Colorectal Cancer
Recruiting1 awardPhase 1
Duarte, California
This trial is studying regorafenib in combination with ipilimumab and nivolumab to see if it can help to treat patients with colorectal cancer that has spread and is resistant to chemotherapy.
Trials for MSI-H Positive Patients
Monoclonal Antibodies
Dostarlimab for Rectal Cancer
Recruiting1 awardPhase 2
Little Rock, Arkansas
This trial is testing a drug called dostarlimab on patients with a specific type of rectal cancer who haven't been treated before. The goal is to see if this drug alone can treat the cancer effectively, so patients might avoid more aggressive treatments like chemotherapy, radiation, and surgery. Dostarlimab (Jemperliâ„¢) has been approved in the EU and USA for treating certain types of cancer.
Chemotherapy Agent
RGX-202-01 Combination Therapy for Colorectal Cancer
Recruiting1 awardPhase 1
Los Angeles, California
This trial is testing a new drug, RGX-202-01, to see if it can shrink tumors in people with gastrointestinal cancer. The study will test different doses of the drug to see what is safe and effective. The study will also test the drug in combination with other drugs that are commonly used to treat gastrointestinal cancer.
Chemotherapy
Nivolumab + Ipilimumab for Colorectal Cancer
Recruiting2 awardsPhase 3
Los Angeles, California
This trial is testing nivolumab with or without ipilimumab as a treatment for metastatic colorectal cancer in patients with microsatellite instability high or mismatch repair deficiency. The goal is to see if the combination therapy is more effective than nivolumab alone and if either treatment is more effective than chemotherapy.
PARP Inhibitor
Niraparib + Panitumumab for Colorectal Cancer
Recruiting1 awardPhase 2
Atlanta, Georgia
This trial studies how well niraparib and panitumumab work together in treating patients with advanced colorectal cancer who have already received treatment. Niraparib blocks enzymes needed for cancer growth, while panitumumab helps the immune system attack cancer cells and stops them from spreading. Panitumumab is a fully human monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is used in the treatment of metastatic colorectal cancer, particularly in patients with wild-type KRAS tumors.
Trials for DMMR Positive Patients
Monoclonal Antibodies
Dostarlimab for Rectal Cancer
Recruiting1 awardPhase 2
Little Rock, Arkansas
This trial is testing a drug called dostarlimab on patients with a specific type of rectal cancer who haven't been treated before. The goal is to see if this drug alone can treat the cancer effectively, so patients might avoid more aggressive treatments like chemotherapy, radiation, and surgery. Dostarlimab (Jemperliâ„¢) has been approved in the EU and USA for treating certain types of cancer.
Chemotherapy Agent
RGX-202-01 Combination Therapy for Colorectal Cancer
Recruiting1 awardPhase 1
Los Angeles, California
This trial is testing a new drug, RGX-202-01, to see if it can shrink tumors in people with gastrointestinal cancer. The study will test different doses of the drug to see what is safe and effective. The study will also test the drug in combination with other drugs that are commonly used to treat gastrointestinal cancer.
Chemotherapy
Nivolumab + Ipilimumab for Colorectal Cancer
Recruiting2 awardsPhase 3
Los Angeles, California
This trial is testing nivolumab with or without ipilimumab as a treatment for metastatic colorectal cancer in patients with microsatellite instability high or mismatch repair deficiency. The goal is to see if the combination therapy is more effective than nivolumab alone and if either treatment is more effective than chemotherapy.
Tyrosine Kinase Inhibitor
Fruquintinib for Colorectal Cancer
Recruiting1 awardPhase 3
Phoenix, Arizona
This trial tests fruquintinib, a drug that blocks signals making cancer cells grow, in patients with advanced colorectal cancer who haven't responded to other treatments. Fruquintinib is a drug that blocks signals making cancer cells grow and has shown significant benefits in previous trials for certain types of lung cancer. It aims to find new options for those whose cancer continues to progress despite other treatments.
Phase 3 Trials
Chemotherapy
Chemotherapy + Radiation for Rectal Cancer
Recruiting1 awardPhase 2 & 3
Birmingham, Alabama
This trial is looking at whether a different combination of chemotherapy drugs (FOLFOX) and selective use of radiation therapy is better than the standard 5FUCMT treatment for locally advanced rectal cancer.
Trials With No Placebo
Educational Videos for Colorectal Cancer
Recruiting1 award1 criteria
Chapel Hill, North Carolina
This trial aims to study how to improve the participation of Latinos in cancer clinical trials. They will recruit 60 Spanish-speaking individuals from a church in Chapel Hill. Participants will attend an educational session and watch
Monoclonal Antibodies
Dostarlimab for Rectal Cancer
Recruiting1 awardPhase 2
Little Rock, Arkansas
This trial is testing a drug called dostarlimab on patients with a specific type of rectal cancer who haven't been treated before. The goal is to see if this drug alone can treat the cancer effectively, so patients might avoid more aggressive treatments like chemotherapy, radiation, and surgery. Dostarlimab (Jemperliâ„¢) has been approved in the EU and USA for treating certain types of cancer.
Antimetabolite
Galunisertib + Chemotherapy for Rectal Cancer
Recruiting1 awardPhase 2
Portland, Oregon
This trial is testing a new drug to treat rectal cancer in combination with chemotherapy and radiation. Tissue and blood samples will also be collected to study the effectiveness of the drug and the immune system's response.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.